Download PDF
Thromb Haemost 1999; 82(01): 145-148
DOI: 10.1055/s-0037-1614644
Scientific and Standardization Committee Communication
Schattauer GmbH

A Soluble Fibrin Standard: Comparable Dose-response with Immunologic and Functional Assays[*]

Bonnie I. McCarron
1   From the Vascular Medicine Unit, Department of Medicine University of Rochester School of Medicine and Dentistry Rochester, New York, USA
,
Victor J. Marder
1   From the Vascular Medicine Unit, Department of Medicine University of Rochester School of Medicine and Dentistry Rochester, New York, USA
,
Joel J. Kanouse
1   From the Vascular Medicine Unit, Department of Medicine University of Rochester School of Medicine and Dentistry Rochester, New York, USA
,
Charles W. Francis
1   From the Vascular Medicine Unit, Department of Medicine University of Rochester School of Medicine and Dentistry Rochester, New York, USA
› Author AffiliationsThis work was supported in part by Grants HL-07152 and HL-30616 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Further Information

Publication History

Received 14 January 1998

Accepted after resubmission 19 February 1999

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

A soluble fibrin (SF) preparation has been developed as a potential standard by the Scientific and Standardization Committee for use in assays evaluating in vitro preparations and patient plasma samples. The SF standard was prepared by reaction of factor XIII-free fibrinogen with thrombin, followed by neutralization with hirudin and solubilization of the fibrin in acetic acid. As characterized by SDS-PAGE, the polypeptide chain structure shows the anticipated loss of fibrinopep-tides and lack of sγ or α chain crosslinking. The standard was added to pooled normal plasma at concentrations from 12.5 μg/ml to 340 μg/ml and tested with four commercially available assays based on immunologic reactions using ELISA or latex agglutination or on t-PA cofactor activity for plasminogen to plasmin conversion. Absolute “soluble fibrin” concentrations were calculated using the manufacturers’ calibrators and showed distinct dose-response relationships for each assay. Expression of the results following log-transformation produced a series of parallel lines, indicating that this SF preparation can serve as a standard, effectively normalizing the disparate proprietary internal calibrators currently used for each assay.

* Report prepared on behalf of the DIC Subcommittee of the SSC


 

  • References

  • 1 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
    CrossrefPubMedGoogle Scholar
  • 2 Lane DA, Ireland H. Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of fibrinopeptide A, fibrinogen fragment Bβ1-42. and β-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-8.
    CrossrefPubMedGoogle Scholar
  • 3 Amiral J, Walenga JM, Fareed J. Development and peformance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Sem Thromb Hemost 1984; 10: 228-42.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170-7.
    CrossrefPubMedGoogle Scholar
  • 5 Kornberg A, Francis CW, Marder VJ. Plasma crosslinked fibrin polymers: Quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normals and patients with acute thrombotic disorders. Blood 1992; 80: 709-17.
    PubMedGoogle Scholar
  • 6 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch-Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coag Fibrinoly 1993; 4: 97-102.
    PubMedGoogle Scholar
  • 7 Schielen WJG, Adams HPHM, van Leuven K, Voskuilen M, Tesser I G, Nieuwenhuizen W. The sequence γ-(312-324) is a fibrin-specific epitope. Blood 1991; 77: 2169-73.
    PubMedGoogle Scholar
  • 8 Nieuwenhuizen W, Hoegee-De Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost 1992; 68: 273-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexes with fibrinogen or its derivatives: Its application to the measurement of soluble fibrin in plasma. Blood 1996; 88: 2109-17.
    PubMedGoogle Scholar
  • 10 Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost 1986; 55: 189-93.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 van Wersch JWJ. Adaptation and evaluation of a chromogenic test procedure for fibrin monomers on a centrifugal analyzer. J Clin Chem Clin Biochem 1990; 28: 169-74.
    PubMedGoogle Scholar
  • 12 Vogel G, Spanuth E. Predictive value of fibrin monomers in postoperative deep vein thrombosis. Klin Wochenschr 1990; 68: 1020-6.
    CrossrefPubMedGoogle Scholar
  • 13 Vogel G, Dempfle C-E, Spannagl M, Leskopf W. The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. Thromb Res 1996; 81: 241-51.
    CrossrefPubMedGoogle Scholar
  • 14 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74: 833-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Donovan D, McGinnis J, Brill-Edwards P, Panju A, Patel A, Weitz JI. Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism. Thromb Haemost 1996; 75: 551-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Brimble KS, Ginsberg JS. Evaluation of the combination of a bedside D-dimer assay and enzyme-linked immunosorbent soluble fibrin assay in patients with suspected venous thromboembolism. Thromb Res 1997; 88: 291-7.
    CrossrefPubMedGoogle Scholar
  • 17 Carville DGM, Dimitrijevic N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpP®): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537-41.
    PubMedGoogle Scholar
  • 18 Lee LV, Eward GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscl Thromb Vasc Biol 1997; 17: 628-33.
    CrossrefPubMedGoogle Scholar
  • 19 Bredbacka S, Blomback M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesth Scand 1993; 37: 125-30.
    CrossrefPubMedGoogle Scholar
  • 20 Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intra-vascular coagulation. Am J Hematol 1996; 51: 255-60.
    CrossrefPubMedGoogle Scholar
  • 21 Bremme K, Blomback M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest 1996; 41: 20-6.
    CrossrefPubMedGoogle Scholar
  • 22 Ostlund E, Bremme K, Wiman B. Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications. Acta Obset Gynecol Scand 1998; 77: 165-9.
    PubMedGoogle Scholar
  • 23 Rahr HB, Danielsen D, Andersen BS, Borris LC, Lassen MR. Poor correlation between soluble fibrin concentrations measured by two commercially available immunoassays. Thromb Res 1996; 81: 607-14.
    CrossrefPubMedGoogle Scholar
  • 24 Wieding JU, Hosius C. Determination of soluble fibrin: A comparison of four different methods. Thromb Res 1992; 65: 745-56.
    CrossrefPubMedGoogle Scholar
  • 25 Halvorsen S, Skjonsberg OH, Godal HC. Comparison of methods for detecting soluble fibrin in plasma from patients with venous thromboembolism. Thromb Res 1991; 61: 341-8.
    CrossrefPubMedGoogle Scholar
  • 26 Friberger P. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1975; 7: 138-45.
    PubMedGoogle Scholar
  • 27 Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin α-chain to fibrin polymerization site “A”: effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coag Fibrinol 1993; 4: 79-86.
    CrossrefPubMedGoogle Scholar
  • 28 Halvorsen S, Skjonsberg OH, Godal HC. Thrombin treated plasma employed as a standard for determination of soluble fibrin. Thromb Res 1993; 72: 305-13.
    CrossrefPubMedGoogle Scholar
  • 29 Pfitzner SA, Dempfle C-K, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost 1997; 78: 1069-78.
    Article in Thieme ConnectPubMedGoogle Scholar